SERDs in Focus: Optimizing Treatment Strategies in HR+ HER2- Breast Cancer - Episode 5
Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials
Dr. Gandhi and Dr. Clifton discuss incorporating imlunestrant plus abemaciclib into treatment sequencing for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (BC), considering factors such as ESR1 mutation status, prior CDK4/6 inhibitor (CDK4/6i) use, and visceral metastases, while also highlighting key trials of selective estrogen receptor degraders (SERDs), including SERENA-2 and OPERA-01.
Video content above is prompted by the following:
- Based on the data seen in the EMBER-3 trial, how do you anticipate incorporating imlunestrant plus abemaciclib into your treatment sequencing for patients with HR+/HER2– metastatic BC? In which patients and in which line of therapy would you consider using this combination?
- Based on subgroup data, how might you consider these factors in your clinical decision-making?
- ESR1 mutation vs wild type
- Prior CDK4/6i
- Duration of prior CDK4/6i
- Presence of visceral metastases
- Based on subgroup data, how might you consider these factors in your clinical decision-making?
- Please highlight other trials of note investigating SERDs in HR+/HER2– BC:
- SERENA-2: camizestrant vs fulvestrant
- OPERA-01: palazestrant vs standard-of-care endocrine therapy
- Any others (eg, EMBER-4, SERENA-4,ELEVATE, etc)
Related Content:
